Parkinson’s Disease as a Risk Factor for Melanoma: A Review

LT Zachary T. Monahan, MD, LCDR Aaron S. Cantor, MD, CDR Kent S. Handfield, MD, FAAD

1Walter Reed National Military Medical Center, Bethesda, MD

ABSTRACT

Objective: To review the literature and place into a quantified context the relationship of Parkinson’s disease diagnosis to a subsequent diagnosis of malignant melanoma, and to briefly explore potential molecular associations between the two diseases.

Methods: The Medline database was queried with terms related to Parkinson’s disease (PD) and malignant melanoma, with use of Boolean operator AND to identify studies involving both diseases. Studies were divided into primary and meta-analyses, with exclusive evaluation of those quantifying risk of malignant melanoma after an established diagnosis of Parkinson’s disease. Critical studies were identified using Medline searches to identify established quantified risk metrics between classic melanoma risk factors and subsequent development of malignant melanoma.

Results: Twelve primary studies and three meta-analyses were evaluated and their risk metrics tabulated. Three studies offered estimated risk of development of malignant melanoma in patients with classic melanoma risk factors. These metrics were also tabulated and compared with the metrics established by the twelve primary studies. This demonstrated a similarity in overall risk of developing malignant melanoma in a patient with a diagnosis of Parkinson’s disease as compared to a patient with classical melanoma risk factors.

Conclusion: It is wise to consider the presence of Parkinson’s disease in a patient as one factor when clinicians decide on the appropriateness of regular full body screening examinations.

INTRODUCTION

Characterizing the association between malignancy and Parkinson’s disease (PD) has been an enormous challenge. While most malignancies are generally observed to be less common in patients with PD, melanoma appears to be a notable exception. Many studies have evaluated the cellular and epidemiological connections, and most conclude that patients with PD are at a higher risk for developing melanoma.1-14 Genetic studies of melanoma and PD have complicated the picture, highlighting exceedingly complex pathogenic models for each disease. Although the understanding of each particular disease has progressed, details of their relationship are elusive.

The relationship between melanoma and PD seems natural, as both diseases involve the biological pigment melanin. In PD, neuromelanin depletion from the brain’s
substantia nigra (SN) is a disease hallmark. In melanoma, eumelanin-producing melanocytes are the malignant cells responsible for disease. These two pigment types share structural similarities, and there is evidence of shared synthetic pathways involving tyrosinase. While the association of both diseases with melanin is intriguing, it remains unclear whether this association is fundamentally related to their pathogenic relationship.

Though the precise molecular relationship continues to elude, further understanding the epidemiology of melanoma and PD may improve screening practices and prevent recent trends in melanoma overdiagnosis. The epidemiology of the two disorders considered together is critical for establishing accurate, evidence-based screening and diagnostic procedures.

**METHODS**

In this review, we first searched the Medline database for studies evaluating the epidemiological link between PD and any form of melanoma, regardless of the time of publication or the particular demographic studied. Results were divided into primary studies and meta-analyses and reviewed separately. Only those primary studies that specifically addressed the increased risk of melanoma after an established PD diagnosis were evaluated further. These primary studies were analyzed for the components of their analyses that addressed this specific association. Corresponding risk metrics were tabulated for each of these studies.

We also searched the MEDLINE database for recent primary studies and meta-analyses evaluating the strength of individual clinical risk factors for developing melanoma. The approximate degree of risk increase for each risk factor was tabulated based on recent meta-analyses to compare the degree of the increased risk of melanoma reported in patients with diagnosed PD.

**RESULTS**

The epidemiology of PD and melanoma is directly relevant to the daily practice of a clinical dermatologist. A quantitative appreciation for melanoma incidence helps answer the following questions:

1. How much elevated risk are patients with PD at for developing melanoma?
2. How does this elevated risk compare to traditional melanoma risk factors?
3. Do skin screening practices need to change based on a PD diagnosis?
4. Do patients with melanoma deserve closer monitoring for early symptoms of PD?

The quantitative epidemiologic association must be considered with regard to the natural history of both diseases. For early detection and screening for melanoma, we focused on the risk of any melanoma after an established PD diagnosis.

Several primary epidemiologic studies and meta-analyses have attempted to quantify the relationship between PD and a subsequent diagnosis of melanoma (Table 1), with the association measures referencing the risk of melanoma diagnosis in a patient with a pre-established PD diagnosis.
Systematic meta-analyses have supported the conclusions of primary studies, strengthening the epidemiologic association by ensuring adequate controls across studied populations for potential confounders, such as age and gender. Huang et al. 2015 showed a pooled odds ratio of developing melanoma of 2.43 (95% CI: 1.77-3.32) for PD patients compared to those without, as determined across multiple studies. Similarly, Liu et al. 2011 found a pooled odds ratio of 3.61 (95% CI: 1.49–8.77). An extensive meta-analysis by Bajaj et al. in 2010 suggested a pooled relative risk of 1.41 (95% CI: 0.90-2.19).

Understanding the above data in the context of other, more classic melanoma risk factors becomes critical to making evidence-based decisions. Despite the disagreement among specialties, task forces, and societies in the U.S. and abroad regarding the frequency and timing of full body skin exams, many dermatologists recommend full-body skin exams for patients who are at notably increased risk for melanoma.

Some of the widely accepted melanoma risk factors include light skin and eye color, patients with multiple atypical nevi, a history of severe sunburns, and a history of prior treated melanomas. The most recent prospective cohort study in Australia found the highest hazard ratios of invasive melanoma to be 2.34 for age >65, 2.13 for the male gender, 4.79 for inability to tan, 4.42 for many moles at age 21, and 2.51 for >21 moles removed in the past. This study stratified risk for both invasive melanomas and any melanoma.

Similar findings are reflected in a recent analysis of the American Academy of Dermatology’s (AAD) Skin Cancer Screening Program. This analysis found the odds ratios for the development of melanoma to be 1.2 for those over age 50, 1.4 for males, 1.4 for the presence of changing moles, 2.0 for the absence of regular visits to a dermatologist, and 3.5 for a history of melanoma. When combined, exposures to several of these risk factors resulted in an odds ratio of 1.0, 1.7, 2.5, and 4.4 for zero to one, two, three, and four to five risk factors, respectively. The “age over 50 years” risk factor may seem to capture the older population associated with a higher risk for PD diagnosis. However, compared to risk metrics for developing melanoma after PD diagnosis, this criterion appears to carry at least half the risk and, by itself, is unlikely to prompt a primary care referral to dermatology for a full-body skin exam.

The most recent and most extensive analysis of the AAD SPOTme skin cancer screening program found the adjusted odds ratio for cutaneous melanoma to be 1.54 for males, 1.38 for patient’s with an uninsured status, 1.28 for patients with no regular access to a dermatologist, 2.54 for personal history of melanoma, 1.65 for a recent change in moles, 1.68 for >26 moles, 1.44 for >30 hours per week in the sun, and 1.39 for 4-6 years of indoor tanning. Beaulieu et al. concluded that targeting these groups will lead to more effective screening campaigns.

Table 2 summarizes the above risk metrics and their ranges to compare the metrics reported in Table 1.

The magnitude of increased for melanoma risk in patients with a PD diagnosis over multiple studies approximates the increased risk for melanoma in patients with multiple classic risk factors, including such critical elements of a patient’s history as a previous melanoma diagnosis. These standard risk factors would typically prompt more thorough and regular skin exams by a dermatologist. Citing this evidence, we advocate for periodic skin exams for people...
with PD, even in the absence of the above more classically appreciated risk factors, patients who would otherwise go unchecked. The requisite shared decision

Table 1. The relationship between PD and a subsequent diagnosis of melanoma.

| Authors            | Publication Date | Study Design   | Risk Metric (95% CI) |
|--------------------|------------------|----------------|----------------------|
| Moller et al.      | March 1995       | Retrospective Cohort | RR: 1.96 (1.1-3.2)   |
| Olsen et al.       | December 2004    | Retrospective Cohort | SIR: 1.95 (1.4-2.6)  |
| Constantinescu et al. | April 2007     | Retrospective Cohort | SER: 3.3 (1.1-7.8)   |
| Driver et al.      | June 2007        | Prospective Cohort | RR: 6.15 (1.77-21.37) |
| Bertoni et al.     | March 2010       | Prospective Cohort | RR: 2.24 (1.21-4.17) |
| Becker et al.      | March 2010       | Case-Control     | OR: 2.72 (0.66-11.12) |
| Lo et al.          | September 2010   | Retrospective Cohort | RR: 1.6 (0.71-3.6)   |
| Schwid et al.      | September 2010   | Prospective Cohort | SIR: 20.9 (9.6-39.7) |
| Sun et al.         | October 2011     | Prospective Cohort | HR: 2.11 (0.21-21.3) |
| Rugbjerg et al.    | October 2013     | Prospective Cohort | SIR: 1.41 (1.09-1.34) |
| Constantinescu et al. | December 2013   | Prospective Cohort | SER: 3.6 (2.2-5.6)   |
| Ryu et al.         | April 2020       | Retrospective Cohort | HR: 2.83 (1.39-5.72) |

Odds ratio (OR), Standardized event ratio (SER), Relative risk (RR), Standardized incidence ratio (SIR), Hazard ratio (HR).

Table 2. Summary of risk metric ranges for commonly considered risk factors for the development of melanoma reported by several recent studies.

| Study                | Risk Metric Range for All Risk Factors Evaluated | Odds ratio (OR), Relative risk (RR), Hazard ratio (HR). |
|----------------------|--------------------------------------------------|------------------------------------------------------|
| Olsen et al. 2018    | HR: 2.13-4.79                                   |                                                     |
| Goldberg et al. 2007 | OR: 1.2-3.5                                     |                                                     |
| Beaulieu et al. 2018 | OR: 1.28-2.54                                    |                                                     |

The absence of common entries is telling; suggested molecular connections between PD and melanoma are numerous but convincing evidence remains scarce. Table 4 outlines some of the prominent suggested molecular connections.34-50 Recent literature is accelerating our understanding of this molecular relationship, and multiple potential connections between the two diseases exist. Several of the molecular candidates outlined in Table 4 are critical players in various protein quality control (PQC) pathways, suggesting that a more developed understanding of this process has the potential to improve understanding of both diseases. The molecular links between the two diseases, however, remains mostly academic. It remains to be seen if understanding the pathways will lead to the identification of new therapies, or otherwise meaningfully improve our ability to combat the human costs of either disease. While studies continue, there are essential things

DISCUSSION

The epidemiologic association between PD and melanoma belies a molecular relationship that has so far remained incompletely characterized. A short list of the commonly associated genes with both melanoma and PD is offered in Table 3.31,32 The absence of common entries is telling; suggested molecular connections between
that we can do in the clinic now, armed with our knowledge of the association of PD and melanoma.

**Table 3.** Proteins and their respective genes are linked to increased susceptibility to melanoma and Parkinson’s disease.

| Proteins (Genes) Linked to Melanoma | Proteins (Genes) Linked to PD |
|------------------------------------|-----------------------------|
| Adrenocortical dysplasia homologue (*ACD*) | Alpha-synuclein (*SNCA*) |
| BRCA-associated protein 1 (*BAP1*) | Dardarin (*LRRK2*) |
| Cyclin-dependent kinase inhibitor 2A (*CDKN2A*) | F-box only protein 7 (*FBXO7*) |
| Cyclin-dependent kinase 4 (*CDK4*) | Microtubule-associated protein tau (*MAPT*) |
| Microphthalmia-associated transcription factor (*MITF*) | Paired immunoglobulin type 2 receptor beta (*PILRB*) |
| Melanocortin 1 receptor (*MC1R*) | Parkin (*PARK2*) |
| Protection of telomeres 1 (*POT1*) | Protein deglycase DJ-1 (*PARK7*) |
| Telomerase reverse transcriptase (*TERT*) | PTEN-induced kinase 1 (*PINK1*) |
| TERF2-interacting protein (*TERF2IP*) | Siglec 3 (*CD33*) |

Based on our review, a diagnosis of PD is a significant risk factor for melanoma. We suggest that the timing and frequency of full-body skin exams are thoughtfully considered for patients diagnosed with PD. While the clinical utility of full-body skin exams in the general population with few to no risk factors for melanoma remains ambiguous, consistent epidemiologic evidence included herein suggests a likely benefit in patients with PD. The diagnosis of PD increases the subsequent risk of developing melanoma at rates similar to established melanoma risk factors, and it should be added to the list of risk factors considered during screening. Given the relative ease, speed, and low risks of a full-body skin exam, dermatologists can directly benefit patients with a diagnosis of PD, lead the specialty in improving our understanding of melanoma, and challenge the field to consider novel factors in melanoma pathogenesis. Other authors have made similar recommendations.33 With such targeting toward higher-risk patients, melanoma screenings will be optimized, increasing detection in higher-risk populations and decreasing overdiagnosis. A more accurate set of risk factors can also help establish a consensus risk threshold to guide screening practices, which has been done in Australia.28

**CONCLUSION**

Finally, our review highlights the need for future studies to characterize the molecular link between melanoma and PD and the outcomes of melanoma diagnosed in patients with PD, such as the stage of melanoma at diagnosis and the relative survival of these patients. These future studies will help us better understand both
### Table 4. Proteins and their respective genes are proposed as potential links between PD and melanoma in the literature

| Gene | Protein       | Proposed Link                                                                                                                                 |
|------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| SNCA | Alpha-synuclein | Mutations in SNCA are rare. Alpha-synuclein’s association with PD is primarily histopathological; abnormal inclusions of alpha-synuclein into so-called Lewy Bodies are a disease hallmark. While mutations can be associated with increased risk, the alpha-synuclein in Lewy Bodies is often genetically wild-type. Increased levels of alpha-synuclein have also recently been found in melanoma cells. |
| PARK2| PARKIN        | An E3 ligase, PARKIN has been linked to PD in, with sequence mutations being important to the association. In fact, mutations in PARK2 are the most frequent cause of autosomal recessive juvenile-onset PD. The studies of PARKIN in the context of melanoma have been mixed; some results suggest that it may function as a tumor suppressor in melanoma cell lines, while others have suggested that PARKIN may promote melanoma proliferation. |
| LRRK2| Dardarin      | Architectural similarities exist between the kinase domain of dardarin and the protein Braf. Braf is encoded by BRAF, which is the most common site of somatic mutations in melanoma. The kinase domain of dardarin has been implicated in PD pathogenesis, with sequence mutations in this gene being the most common cause of autosomal dominant PD. |
| PARK7| DJ-1          | The protein deglycase DJ-1 has been associated with PD, with data suggesting that it interacts with alpha-synuclein to prevent its adoption into pathologic conformations. Results from DJ-1 knockout mice suggest that loss of DJ-1 function enhances melanoma metastasis. |
| PINK1| Pink1         | Implicated in the degradation of abnormal mitochondria, mutations in pink1 have an association with PD. It is also associated with malignancy development in general, with evidence that mutations in PINK1 promote tumorigenesis and metastasis. |

Diseases’ underlying pathology and promote more accurate prognostic models.

**Abbreviations:**
- PD: Parkinson’s disease
- PQC: Protein quality control
- SN: Substantia nigra

**Conflict of Interest Disclosures:** The authors have no conflict of interest to declare. No prior presentation of data to report. Drs. Monahan, Cantor, and Handfield are military service members of the U.S. Government. This work was prepared as part of their official duties. Title 17, USC, § 105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, USC § 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the United States Government.

**Funding:** None
References:
1. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. *Cancer Epidemiol Biomarkers Prev.* 2007;16(6):1260-1265. doi:10.1158/1055-9966.EPI-07-0038
2. Bajaj A, Driver JA, Scherhammer ES. Parkinson’s disease and cancer risk: a systematic review and meta-analysis. *Cancer Causes Control.* 2010;21(5):697-707. doi:10.1007/s10552-009-9497-6
3. Sun L-M, Liang J-A, Chang S-N, Sung F-C, Muo C-H, Kao C-H. Analysis of Parkinson’s disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study. *Neuroepidemiology.* 2011;37(2):114-119. doi:10.1159/000331489
4. Schwid SR, Bausch J, Oakes D, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease. *Mov Disord.* 2010;25(12):1801-1808. doi:10.1002/mds.23006
5. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: a population-based study. *Parkinsonism Relat Disord.* 2010;16(3):186-190. doi:10.1016/j.parkreldis.2009.11.005
6. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM. Comorbid cancer in Parkinson’s disease. *Mov Disord.* 2010;25(12):1809-1817. doi:10.1002/mds.23246
7. Bertoni JM, Arlette JP, Fernandez HH, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. *Arch Neurol.* 2010;67(3):347-352. doi:10.1001/archneurol.2010.1
8. Constantinescu R, Romer M, Kieburzt K, DATATOP Investigators of the Parkinson Study Group. Malignant melanoma in early Parkinson’s disease: the DATATOP trial. *Mov Disord.* 2007;22(5):720-722. doi:10.1002/mds.21273
9. Constantinescu R, Elm J, Auinger P, et al. Malignant melanoma in early-treated Parkinson’s disease: the NET-PD trial. *Mov Disord.* 2014;29(2):263-265. doi:10.1002/mds.25734
10. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. *Int J Cancer.* 2012;131(8):1904-1911. doi:10.1002/ijc.27443
11. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. *Neurology.* 2011;76(23):2002-2009. doi:10.1212/WNL.0b013e31821e554e
12. Ryu HJ, Park J-H, Choi M, et al. Parkinson’s Disease and Skin Cancer Risk: A Nationwide Population-Based Cohort Study in Korea. *J Eur Acad Dermatol Venereol.* Published online April 14, 2020. doi:10.1111/jdv.16462
13. Huang P, Yang X-D, Chen S-D, Xiao Q. The association between Parkinson’s disease and melanoma: a systematic review and meta-analysis. *Transl Neurodegener.* 2015;4:21. doi:10.1186/s40035-015-0044-y
14. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H. Atypical cancer pattern in patients with Parkinson’s disease. *Br J Cancer.* 2005;92(1):201-205. doi:10.1038/sj.bjc.6602279
15. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? *J Neurochem.* 1992;59(3):1080-1089. doi:10.1111/j.1471-4159.1992.tb08350.x
16. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson’s disease. *Brain Res.* 1992;581(2):283-291. doi:10.1016/0006-8993(92)90719-p
17. Haining R, Achat-Mendes C. Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator. *Neural Regen Res.* 2017;12(3):372. doi:10.4103/1673-5374.202928
18. Jimbow K, Miyake Y, Homma K, et al. Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma. *Cancer Res.* 1984;44(3):1128-1134.
19. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double K. Neuromelanin in human...
29. Goldberg MS, Doucette JT, Lim HW, Spencer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. *MP, Mol Pathol*. 2001;54(6):414-418.

28. Olsen CM, Pandeya N, Thompson BS, et al. Risk Stratification for Melanoma: Models Derived and Validated in a Purpose-Designed Prospective Cohort. *J Natl Cancer Inst*. 2018;110(10):1075-1083. doi:10.1093/jnci/djy023

27. Rigel DS. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-2005. *J Am Acad Dermatol*. 2007;57(1):60-66. doi:10.1016/j.jaad.2007.02.010

26. Cho E, Rosner BA, Colditz GA. Risk factors and individual probabilities of melanoma for whites. *J Clin Oncol*. 2005;23(12):2669-2675. doi:10.1200/JCO.2005.11.108

25. Cho E, Rosner BA, Colditz GA. Risk factors and individual probabilities of melanoma for whites. *J Clin Oncol*. 2005;23(12):2669-2675. doi:10.1200/JCO.2005.11.108

24. Hübner J, Waldmann A, Eisemann N, et al. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening: *European Journal of Cancer Prevention*. 2018;27(6):563-569. doi:10.1097/CEJ.0000000000000392

23. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2016;316(4):242-243. doi:10.1001/jama.2016.8465

22. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson’s disease. *BMJ*. 1995;310(6993):1500-1501. doi:10.1136/bmj.310.6993.1500

21. Glasziou PP, Jones MA, Pathirana T, Barratt AL, Bell KJ. Estimating the magnitude of cancer overdiagnosis in Australia. *Medical Journal of Australia*. 2020;212(4):204-210. doi:10.5694/mja2.50455

20. Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. *MP, Mol Pathol*. 2001;54(6):414-418.

19. Beaulieu D, Tsao H, Michaud DS, Okhoverat J-P, Halpern AC, Geller AC. Factors associated with suspected nonmelanoma skin cancers, dysplastic nevus, and cutaneous melanoma among first-time SPOTme screening program participants (2009-2010). *Journal of the American Academy of Dermatology*. Published online December 2018:S0190962218330524. doi:10.1016/j.jaad.2018.12.010

18. Olsen JH. Occurrence of different cancers in patients with Parkinson’s disease. *BMJ*. 1995;310(6993):1500-1501. doi:10.1136/bmj.310.6993.1500

17. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2016;316(4):429-435. doi:10.1001/jama.2016.701. doi:10.1002/mds.25499

16. Cho E, Rosner BA, Colditz GA. Risk factors and individual probabilities of melanoma for whites. *J Clin Oncol*. 2005;23(12):2669-2675. doi:10.1200/JCO.2005.11.108

15. Potter TP, Bollen S, Grimbergen AJEM, et al. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. *Int J Cancer*. 2019;144(10):2453-2464. doi:10.1002/ijc.31984

14. Li Yi, Wong G, Humphrey J, Raj T. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data. *Nat Commun*. 2019;10(1):994. doi:10.1038/s41467-019-08912-9

13. Dalvin LA, Damento GM, Abbott BA, Hodge DO, Pulido JS. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. *Mayo Clin Proc*. 2017;92(7):1070-1079. doi:10.1016/j.mayocp.2017.03.014

12. Turriani E, Lázaro DF, Ryazanov S, et al. Treatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. *Proc Natl Acad Sci USA*. 2017;114(25):E4971-E4977. doi:10.1073/pnas.1700200114

11. Kasten M, Klein C. The many faces of alpha-synuclein mutations: The Many Faces of Alpha-Synuclein Mutations. *Mov Disord*. 2013;28(6):697-701. doi:10.1002/mds.25499

10. de Oliveira GAP, Silva JL. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease. *Commun Biol*. 2019;2:374. doi:10.1038/s42003-019-0598-9

9. Rodriguez-Leyva I, Chi-Ahumada E, Mejia M, et al. The Presence of Alpha-Synuclein in Skin from Melanoma and Patients with Parkinson’s Disease. *Mov Disord Clin Pract*. 2017;4(5):724-732. doi:10.1002/mdc3.12494

8. Shimura H, Hattori N, Kubo S i, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet*. 2000;25(3):302-305. doi:10.1038/77060

7. Li N, Wang L, Zhang J, et al. Whole exome sequencing in early-onset Parkinson’s disease among ethnic Chinese. *Neurobiol Aging*. 2019;73:246-254. doi:10.1016/j.nia.2017.03.014

6. Li Yi, Wong G, Humphrey J, Raj T. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data. *Nat Commun*. 2019;10(1):994. doi:10.1038/s41467-019-08912-9

5. Potter TP, Bollen S, Grimbergen AJEM, et al. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. *Int J Cancer*. 2019;144(10):2453-2464. doi:10.1002/ijc.31984

4. Li Yi, Wong G, Humphrey J, Raj T. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data. *Nat Commun*. 2019;10(1):994. doi:10.1038/s41467-019-08912-9

3. Dalvin LA, Damento GM, Abbott BA, Hodge DO, Pulido JS. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. *Mayo Clin Proc*. 2017;92(7):1070-1079. doi:10.1016/j.mayocp.2017.03.014

2. Turriani E, Lázaro DF, Ryazanov S, et al. Treatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. *Proc Natl Acad Sci USA*. 2017;114(25):E4971-E4977. doi:10.1073/pnas.1700200114

1. Kasten M, Klein C. The many faces of alpha-synuclein mutations: The Many Faces of Alpha-Synuclein Mutations. *Mov Disord*. 2013;28(6):697-701. doi:10.1002/mds.25499

---

**SKIN**

---

Copyright 2021 The National Society for Cutaneous Medicine 510
40. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. 1998;392(6676):605-608. doi:10.1038/33416

41. Hu H-H, Kannengiesser C, Lesage S, et al. PARKIN Inactivation Links Parkinson’s Disease to Melanoma. *J Natl Cancer Inst*. 2016;108(3). doi:10.1093/jnci/djv340

42. Lee YS, Jung YY, Park MH, et al. Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination. *Cancer Lett*. 2018;433:156-164. doi:10.1016/j.canlet.2018.07.007

43. Pan T, Li X, Jankovic J. The association between Parkinson’s disease and melanoma: Association between PD and Melanoma. *Int J Cancer*. 2011;128(10):2251-2260. doi:10.1002/ijc.25912

44. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417(6892):949-954. doi:10.1038/nature00766

45. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. *Nat Neurosci*. 2006;9(10):1231-1233. doi:10.1038/nn1776

46. Di Fonzo A, Rohé CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. *Lancet*. 2005;365(9457):412-415. doi:10.1016/S0140-6736(05)17829-5

47. Zondler L, Miller-Fleming L, Repici M, et al. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson’s disease. *Cell Death Dis*. 2014;5:e1350. doi:10.1038/cddis.2014.307

48. Chien C-H, Lee M-J, Liou H-C, Liou H-H, Fu W-M. Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice. *PLoS ONE*. 2015;10(2):e0115827. doi:10.1371/journal.pone.0115827

49. Narendra DP, Jin SM, Tanaka A, et al. PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin. Green DR, ed. *PLoS Biol*. 2010;8(1):e1000298. doi:10.1371/journal.pbio.1000298

50. O’Flanagan CH, Morais VA, Wurst W, De Strooper B, O’Neill C. The Parkinson’s gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes.